EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Implications of β-Arrestin biased signaling by angiotensin II type 1 receptor for cardiovascular drug discovery and therapeutics

Khuraijam Dhanachandra Singh, Sadashiva S Karnik

Cellular Signalling · 2024-12 · 124 · 111410

DOI: 10.1016/j.cellsig.2024.111410 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cellular Signalling, 2024-12. Verfasst von Khuraijam Dhanachandra Singh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland Clinic…. Hauptthemen laut MEDLINE: Receptor, Angiotensin, Type 1, beta-Arrestins, Signal Transduction, Drug Discovery. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health, Lupus Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiotensin II receptors, Type 1 (AT1R) and Type 2 (AT2R) are 7TM receptors that play critical roles in both the physiological and pathophysiological regulation of the cardiovascular system. While AT1R blockers (ARBs) have proven beneficial in managing cardiac, vascular and renal maladies they cannot completely halt and reverse the progression of pathologies. Numerous experimental and animal studies have demonstrated that β-arrestin biased AT1R-ligands (such as SII-AngII, S1I8, TRV023, and TRV027) offer cardiovascular benefits by blocking the G protein signaling while retaining the β-arrestin signaling. However, these ligands failed to show improvement in heart-failure outcome over the placebo in a phase IIb clinical trial. One major limitation of current β-arrestin biased AT1R-ligands is that they are peptides with short half-lives, limiting their long-term efficacy in patients. Additionally, β-arrestin biased AT1R-ligand peptides, may inadvertently block AT2R, a promiscuous receptor, potentially negating its beneficial effects in post-myocardial infarction (MI) patients. Therefore, developing a small molecule β-arrestin biased AT1R-ligand with a longer half-life and specificity to AT1R could be more effective in treating heart failure. This approach has the potential to revolutionize the treatment of cardiovascular diseases by offering more sustained and targeted therapeutic effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Angiotensin, Type 1beta-ArrestinsSignal TransductionDrug DiscoveryHumansAnimalsCardiovascular AgentsLigandsAngiotensin II Type 1 Receptor Blockers

Stichwörter der Autor:innen

ARBsAT1RCardiovascular diseasesSII-AngIITRV027β-Arrestin biased ligand

Substanzen

Receptor, Angiotensin, Type 1beta-ArrestinsCardiovascular AgentsLigandsAngiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland Clinic, USA. Electronic address: khuraid@ccf.org.
  • Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland Clinic, USA. Electronic address: karniks@ccf.org.

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health
  • Lupus Research Institute
  • Cleveland Clinic

Zitieren

APA

Singh, K. D., & Karnik, S. S. (2024). Implications of β-Arrestin biased signaling by angiotensin II type 1 receptor for cardiovascular drug discovery and therapeutics. Cellular Signalling, 124, 111410. https://doi.org/10.1016/j.cellsig.2024.111410

Vancouver

Singh KD, Karnik SS. Implications of β-Arrestin biased signaling by angiotensin II type 1 receptor for cardiovascular drug discovery and therapeutics. Cellular Signalling. 2024;124:111410. doi:10.1016/j.cellsig.2024.111410

BibTeX
@article{Singh2024,
  author = {Singh, Khuraijam Dhanachandra and Karnik, Sadashiva S},
  title = {Implications of β-Arrestin biased signaling by angiotensin II type 1 receptor for cardiovascular drug discovery and therapeutics},
  journal = {Cellular Signalling},
  year = {2024},
  volume = {124},
  pages = {111410},
  doi = {10.1016/j.cellsig.2024.111410}
}
Kostenlos starten →